Literature DB >> 18419395

Varicella vaccination in Japan, South Korea, and Europe.

Catherine Sadzot-Delvaux1, Bernard Rentier, Peter Wutzler, Yoshizo Asano, Sadao Suga, Tetsushi Yoshikawa, Stanley A Plotkin.   

Abstract

The most extensive use of varicella vaccine has been in the United States and Canada, where it is universally recommended. However, a number of other countries now have recommendations for use of the vaccine, which has been expanding in Europe and Latin America. In this article, we review information concerning varicella vaccination in Japan, where the vaccine was first developed, and in South Korea and parts of Europe. Despite the worldwide availability of an efficient vaccine, varicella vaccination policy is highly variable from country to country. The recent development of a tetravalent vaccine against measles, mumps, rubella, and varicella could modify this variability in the future. It is evident that efforts to control varicella will spread gradually to all continents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18419395     DOI: 10.1086/522163

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Varicella vaccination coverage of children under two years of age in Germany.

Authors:  Annicka M Reuss; Marcel Feig; Lutz Kappelmayer; Anette Siedler; Tim Eckmanns; Gabriele Poggensee
Journal:  BMC Public Health       Date:  2010-08-19       Impact factor: 3.295

Review 2.  Economic evaluation of Varicella vaccination: results of a systematic review.

Authors:  Brigid Unim; Rosella Saulle; Sara Boccalini; Cristina Taddei; Vega Ceccherini; Antonio Boccia; Paolo Bonanni; Giuseppe La Torre
Journal:  Hum Vaccin Immunother       Date:  2013-07-03       Impact factor: 3.452

3.  Varicella vaccine uptake in Shandong Province, China.

Authors:  Aiqiang Xu; Qing Xu; Xueqiang Fang; Stephanie Bialek; Chengbin Wang
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

Review 4.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

5.  Seropositivity of Varicella zoster virus in vaccinated Korean children and MAV vaccine group.

Authors:  Ui Yoon Choi; Dong Ho Huh; Jong Hyun Kim; Jin Han Kang
Journal:  Hum Vaccin Immunother       Date:  2016-08-02       Impact factor: 3.452

6.  Genotype of varicella-zoster virus isolates in South Korea.

Authors:  Kye-Hyung Kim; Young Ju Choi; Kyoung-Ho Song; Wan Beom Park; Jae-Hyun Jeon; Sang-Won Park; Hong Bin Kim; Nam Joong Kim; Myoung-Don Oh
Journal:  J Clin Microbiol       Date:  2011-03-16       Impact factor: 5.948

7.  Efficacy of varicella (VZV) vaccination: an update for the clinician.

Authors:  Lili Wang; Lucy Zhu; Hua Zhu
Journal:  Ther Adv Vaccines       Date:  2016-01-01

8.  Varicella-zoster virus: molecular controls of cell fusion-dependent pathogenesis.

Authors:  Stefan L Oliver; Momei Zhou; Ann M Arvin
Journal:  Biochem Soc Trans       Date:  2020-12-18       Impact factor: 5.407

9.  Trends in varicella and herpes zoster epidemiology before and after the implementation of universal one-dose varicella vaccination over one decade in South Korea, 2003-2015.

Authors:  Jae-Ki Choi; Sun Hee Park; Sanghyun Park; Su-Mi Choi; Si-Hyun Kim; Dong-Gun Lee; Jin-Hong Yoo; Jung-Hyun Choi; Jin Han Kang
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

10.  Examination of links between herpes zoster incidence and childhood varicella vaccination.

Authors:  Craig M Hales; Rafael Harpaz; M Riduan Joesoef; Stephanie R Bialek
Journal:  Ann Intern Med       Date:  2013-12-03       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.